Zacks holds faith in Hospira; Indian drugmakers share ops efficiency tricks;

> Zacks has upgraded its rating on Hospira ($HSP) to neutral, from underperform; "negatives associated with the quality control issues have been priced into the stock," it said, and "[w]e believe the company's top and bottom-lines will rebound once the ongoing manufacturing issues get resolved." Item

> The LAZORR alliance of Indian drugmakers--Lupin, Aurobindo, Zydus, Orchid, Ranbaxy and Dr. Reddy's--has so far shared efficiency-improvement tactics for power and water savings. News

> Baxter ($BAX) is taking a dive into the biosimilars pool with Momenta Pharmaceuticals. Story

> Lundbeck ($LUN:DC) says it "is no longer able" to manufacture Mebaral CIV mephobarbital tablets and remaining inventory will expire in March. FDA list

> Botox sales are giving Allergan ($AGN) a boost--the pharma giant expects to create 200 jobs over four years at its plant in Ireland. Report

> Pacira Pharmaceuticals ($PCRX) projects commercial-level availability this coming April for Exparel, its non-opioid postsurgical analgesic approved by the FDA in October. Release

> Indian inspectors will conduct a 10-day tour next month of four Chinese bulk drug suppliers. Story

> Merck's ($MRK) life sciences division EMD Millipore will serve on the faculty of the Centre for Pharmaceutical Information and Engineering Research at Peking University, China. News

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.